. The company’s pipeline involves 4 medical-stage therapies. Its most Sophisticated drug candidate is ROS1 inhibitor taletrectinib for dealing with lung most cancers. Nuvation is completing two section 2 pivotal studies on taletrectinib. Musk appointed Linda Yaccarino CEO of X Corp., the